The Filing Desk

Macrogenics vs Regenxbio

Macrogenics MGNX · Regenxbio RGNX · Biotechnology

Regenxbio reported revenue of $170 million in fiscal 2025, about the same as Macrogenics' $150 million in fiscal 2025. Macrogenics' revenue fell 0.3% in its latest year, and Regenxbio's grew 104.5%. Macrogenics had an operating margin of -48.7%, against -94.6% at Regenxbio. Free cash flow was −$83 million at Macrogenics and −$126 million at Regenxbio.

Side by side

MacrogenicsRegenxbio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$150M$170M
Revenue growth−0.3%104.5%
Revenue growth a year, last 5 years7.3%2.0%
Gross margin100.0%—
Operating margin−48.7%−94.6%
Net margin−49.9%−113.8%
Free cash flow−$83M−$126M
Free cash flow margin−55.5%−74.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count0.8%4.2%
Last close$1.98$7.18
P/E at the last close——
Insider trades, last 12 monthssold $129,086bought $949,541, sold $939,970
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
MacrogenicsRegenxbio
Operating margin
Percent of revenue
MacrogenicsRegenxbio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MacrogenicsRegenxbio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Macrogenics and Regenxbio pages.